Skip to main content
. 2024 Aug 30;89:102019. doi: 10.1016/j.molmet.2024.102019

Figure 8.

Figure 8

Semaglutide and tirzepatide do not reduce the number of activated microglia or reactive astroglia, or attenuate dysregulated gene expression related to neurodegeneration in the hippocampus of 6-month-old 5XFAD mice. (A) Representative images of IBA1+ cells (green), GFAP+ cells (red), or co-stained with both IBA1 and GFAP antibodies (bottom panel) in the hippocampus (Hippo) or subiculum (Sub) of 6-month-old WT and 5XFAD mice treated with semaglutide (25 nmol/kg), tirzepatide (10 nmol/kg), or vehicle (saline). Scale bars represent 300 μm. Areas of interest are encircled by dashed lines. (B–E) Quantification of the number of IBA1+ cells per area (B, C) and the number of GFAP+ cells per area (D, E) in the hippocampus of female (♀) and male (♂) WT and 5XFAD mice. (F–M) Quantitative PCR analysis of transcript levels of Trem2 (F), Tyrobp (G), Clec7a (H), Cd68 (I), Ccl2 (J), Cxcl10 (K), Gfap (L) and Il1b (M) in the hippocampus of 6-month-old female (♀) and male (♂) WT and 5XFAD mice treated with semaglutide (25 nmol/kg), tirzepatide (10 nmol/kg), or vehicle (saline). Ppia was used as a reference gene for normalization. Data for (F–M) were analyzed by 2-way ANOVA with Sidak's post-hoc test for comparison of vehicle vs. treatment and for (B–E) by 1-way ANOVA with Tukey's post-hoc test. #p < 0.05, ##p < 0.01 ###p < 0.001, ####p < 0.0001 WT vs. 5XFAD mice. Data are represented as means ± SD. n = 3–12 in each group of vehicle (Veh)-, semaglutide (Sema)-, or tirzepatide (TZP)-treated mice.